| Literature DB >> 35226084 |
Morgan J Katz1, Pranita D Tamma2, Sara E Cosgrove2, Melissa A Miller3, Prashila Dullabh4, Therese A Rowe5, Roy Ahn6, Kathleen Speck7, Yue Gao4, Savyasachi Shah4, Robin L P Jump8,9.
Abstract
IMPORTANCE: Antibiotic overuse in long-term care (LTC) is common, prompting calls for antibiotic stewardship programs (ASPs) designed for specific use in these settings. The optimal approach to establish robust, sustainable ASPs in LTC facilities is unknown.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35226084 PMCID: PMC8886516 DOI: 10.1001/jamanetworkopen.2022.0181
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Characteristics of Participating Long-term Care Sites
| Characteristics | Sites, No. (%) (N = 439) |
|---|---|
| Certified beds in facility, mean (SD) [range] | 124.3 (96.0) [18-874] |
| Bed capacity | |
| 0-74 | 106 (24.1) |
| 75-149 | 229 (52.2) |
| ≥150 | 104 (23.7) |
| Ownership | |
| Hospital-based | 60 (13.7) |
| Nonhospital–based | |
| Owned by a larger system | 246 (56.0) |
| Not owned by a larger system | 133 (30.3) |
| Proportion of residents in short-stay beds | |
| <25% | 233 (53.1) |
| ≥25% and <50% | 70 (15.9) |
| ≥50% and less than 75% | 45 (10.3) |
| ≥75% | 91 (20.7) |
| Community setting | |
| Urban | 108 (24.6) |
| Suburban | 156 (35.5) |
| Rural | 175 (39.9) |
Characteristics of Antibiotic Stewardship Programs (ASPs) at Participating Long-term Care Sites at Baseline and End of Safety Program
| Assessed domains | Assessed items | Sites, No. (%) | ||
|---|---|---|---|---|
| Baseline (n = 439) | End of program (n = 367) | |||
| Accountability | Infection prevention and control nurse involved with ASP | 363 (82.7) | 341 (92.9) | <.001 |
| Medical director involved with the ASP | 273 (62.2) | 257 (70.0) | .02 | |
| Consultant pharmacist working at the facility | 420 (95.7) | 353 (96.2) | .71 | |
| Actions to improve antibiotic use | In-service training to nurses on topics related to antibiotic use | 328 (74.7) | 331 (90.2) | <.001 |
| Protocols for diagnosis and treatment of common infection syndromes | 287 (65.4) | 279 (76.0) | .001 | |
| Antibiotic prescribing recommendations for facility | 213 (48.5) | 205 (55.9) | .04 | |
| Working with the contracted laboratory to develop antibiogram | 194 (44.2) | 191 (52.0) | .03 | |
| Postprescription review with feedback of select antibiotics | 166 (37.8) | 223 (60.8) | <.001 | |
| Formulary restriction of some antibiotics | 66 (15.0) | 77 (21.0) | .03 | |
| At least one of the above | 402 (91.6) | 362 (98.6) | <.001 | |
| All activities above | 28 (6.4) | 41 (11.2) | .02 | |
| Antibiotic use tracking | Antibiotic starts | 296 (67.4) | 327 (89.1) | <.001 |
| Antibiotic DOT per 1000 resident-days | 176 (40.1) | 269 (73.3) | <.001 | |
| Defined daily doses per 1000 resident-days | 40 (9.1) | 89 (24.3) | <.001 | |
| At least one of the above tracking methods | 384 (87.5) | 358 (97.5) | <.001 | |
Abbreviation: DOT, days of antibiotic therapy.
Compared with baseline, 367 of 439 (83.6%) of participating facilities completed the survey. Facilities that were neither hospital-based nor part of a larger system were more likely to complete the final assessment (126/133 facilities [94.7%] vs 51/60 [85%] for hospital-based facilities and 190/246 [77.2%] for facilities that are not hospital-based but part of a larger health system; P < .001), as were facilities with fewer than 25% short stays (205/233 facilities [88.0%] vs 162/206 [78.6%] for facilities with ≥25% short stay; P = .009).
Changes in Antibiotic Use, Urine Cultures Collected, and Clostridioides difficile LabID Events
| Outcomes | Rate per 1000 resident-days | Difference (95% CI) | ||
|---|---|---|---|---|
| Baseline (n = 410) | End of program (n = 410) | |||
| Antibiotic starts | ||||
| All antibiotics | 7.89 | 7.48 | –0.41 (–0.76 to –0.07) | .02 |
| Fluoroquinolones | 1.49 | 1.28 | –0.21 (–0.35 to –0.08) | .002 |
| Piperacillin-tazobactam | 0.09 | 0.11 | 0.02 (–0.01 to 0.04) | .13 |
| Third-generation cephalosporins | 0.80 | 0.74 | –0.06 (–0.14 to 0.02) | .15 |
| Ceftazidime/cefepime | 0.09 | 0.13 | 0.04 (–0.004 to 0.08) | .08 |
| Antibiotic days of therapy | ||||
| All antibiotics | 64.10 | 61.05 | –3.05 (–6.34 to 0.23) | .07 |
| Fluoroquinolones | 10.6 | 9.41 | –1.20 (–2.15 to –0.24) | .01 |
| Piperacillin-tazobactam | 2.18 | 3.01 | 0.83 (–0.17 to 1.84) | .10 |
| Third-generation cephalosporins | 5.48 | 4.72 | –0.76 (–1.44 to –0.88) | .03 |
| Ceftazidime/cefepime | 1.41 | 2.19 | 0.78 (0.07 to 1.49) | .03 |
| Urine cultures collected | 3.01 | 2.63 | –0.38 (–0.61 to –0.15) | .001 |
| 1.66 | 1.50 | –0.16 (–0.64 to 0.33) | .52 | |
Abbreviation: LabID, laboratory-identified.
Indicates significant difference (P < .05) between the baseline (January-February 2019) and study completion periods (November-December 2019).
Differences in Antibiotic Use Stratified by Facility Engagement
| Engagement measure | Nursing homes, No. (%) (n = 439) | Difference per 1000 resident-days (95% CI) | |
|---|---|---|---|
| Antibiotic starts | Antibiotic days of therapy | ||
| Webinars attended | |||
| None | 82 (18.7) | 0.40 (–0.55 to 1.35) | 3.51 (–6.73 to 13.75) |
| Low (1-7) | 254 (57.9) | –0.29 (–0.74 to 0.17) | –1.85 (–6.07 to 2.37) |
| High (≥8) | 103 (23.5) | –1.12 (–1.75 to –0.49) | –9.97 (–15.37 to –4.56) |
| Webinars attended with educational credit claimed | |||
| None | 295 (67.2) | –0.35 (–0.78 to 0.08) | –1.99 (–6.18 to 2.21) |
| Low (1-7) | 83 (18.9) | –0.31 (–1.12 to 0.49) | –2.5 (–9.79 to 4.8) |
| High (≥8) | 61 (13.9) | –0.77 (–1.62 to 0.07) | –7.92 (–14.93 to –0.92) |
Engagement measured by site based on a minimum of 1 participant.
Indicates a significant difference (P < .05) between the baseline (January-February 2019) and end of program periods (November-December 2019).